Feedback from stakeholders by theme for the consultation on the revised fee proposal for drugs and medical devices
The table below lists feedback we received for the consultation on the revised fee proposal for drugs and medical devices. The feedback is available to members of the public upon request, for the sole purpose of ensuring greater transparency. To request a copy send your request by email, citing the submission number, to: HC.CRO-BRC.SC@canada.ca
| Submission number | Stakeholder Name | Association / Company | Product | Theme |
|---|---|---|---|---|
| 1 | Sandra Gordey | Alberta Health Services | Radiopharmaceutical Drug | Mitigation Measures |
| 2 | Tina Roy | Allergan Inc | Pharmaceuticals (Innovator/Biologic Drugs | Annual Fee Adjustment |
| 3 | Tina Roy | Allergan Inc | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 4 | Caroline Piché | Association pour le Développement et l'Innovation en Chimie au Québec (ADICQ) | Disinfectants | Fee Setting |
| 5 | Caroline Piché | Association pour le Développement et l'Innovation en Chimie au Québec (ADICQ) | Disinfectants | Fee Setting |
| 6 | Caroline Piché | Association pour le Développement et l'Innovation en Chimie au Québec (ADICQ) | Disinfectants | Fee Setting |
| 7 | Caroline Piché | Association pour le Développement et l'Innovation en Chimie au Québec (ADICQ) | Disinfectants | Fee Setting |
| 8 | Caroline Piché | Association pour le Développement et l'Innovation en Chimie au Québec (ADICQ) | Disinfectants | Fee Setting |
| 9 | Regulatory Affairs | AstraZeneca Canada | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 10 | Regulatory Affairs | AstraZeneca Canada | Pharmaceuticals (Innovator/Biologic Drugs | Performance Standards |
| 11 | Regulatory Affairs | AstraZeneca Canada | Pharmaceuticals (Innovator/Biologic Drugs | Penalty Provision |
| 12 | Biogen Canada | Biogen Canada | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 13 | Biogen Canada | Biogen Canada | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 14 | Ron Boch | Biogen Canada | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 15 | Ron Boch | BIOTECanada | Pharmaceuticals (Innovator/Biologic Drugs | Mitigation Measures |
| 16 | Maggy Mouradian | Boehringer Ingelheim | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 17 | Maggy Mouradian | Boehringer Ingelheim | Pharmaceuticals (Innovator/Biologic Drugs | Annual Fee Adjustment |
| 18 | Maggy Mouradian | Boehringer Ingelheim | Pharmaceuticals (Innovator/Biologic Drugs | Performance Standards |
| 19 | Maggy Mouradian | Boehringer Ingelheim | Pharmaceuticals (Innovator/Biologic Drugs | Penalty Provision |
| 20 | Maggy Mouradian | Boehringer Ingelheim | Pharmaceuticals (Innovator/Biologic Drugs | Timing of Payment |
| 21 | Maggy Mouradian | Boehringer Ingelheim | Pharmaceuticals (Innovator/Biologic Drugs | Specific Fee Line Changes |
| 22 | Jean Szkotnicki | Canadian Animal Health Institute (CAHI) | Veterinary Drugs | Fee Setting |
| 23 | Jean Szkotnicki | Canadian Animal Health Institute (CAHI) | Veterinary Drugs | Annual Fee Adjustment |
| 24 | Jean Szkotnicki | Canadian Animal Health Institute (CAHI) | Veterinary Drugs | Small Business |
| 25 | Jean Szkotnicki | Canadian Animal Health Institute (CAHI) | Veterinary Drugs | Performance Standards |
| 26 | Jean Szkotnicki | Canadian Animal Health Institute (CAHI) | Veterinary Drugs | Timing of Payment |
| 27 | Jean Szkotnicki | Canadian Animal Health Institute (CAHI) | Veterinary Drugs | Specific Fee Line Changes |
| 28 | Jean Szkotnicki | Canadian Animal Health Institute (CAHI) | Veterinary Drugs | Mitigation Measures |
| 29 | Terri Drover | Canadian Association for Pharmacy Distribution Management (CAPDM) | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 30 | Terri Drover | Canadian Association for Pharmacy Distribution Management (CAPDM) | Pharmaceuticals (Innovator/Biologic Drugs | Penalty Provision |
| 31 | Jim Keon | Canadian Generic Pharmaceutical Association (CGPA) | Generics | Fee Setting |
| 32 | Jim Keon | Canadian Generic Pharmaceutical Association (CGPA) | Generics | Small Business |
| 33 | Jim Keon | Canadian Generic Pharmaceutical Association (CGPA) | Generics | Mitigation Measures |
| 34 | Jim Keon | Canadian Generic Pharmaceutical Association (CGPA) | Generics | Penalty Provision |
| 35 | Jim Keon | Canadian Generic Pharmaceutical Association (CGPA) | Generics | Timing of Payment |
| 36 | Jim Keon | Canadian Generic Pharmaceutical Association (CGPA) | Generics | Specific Fee Line Changes |
| 37 | Wayne A. Burwash | Canadian Quarter Horse Association | Veterinary Drugs | Fee Setting |
| 38 | Wayne A. Burwash | Canadian Quarter Horse Association | Veterinary Drugs | Performance Standards |
| 39 | Corlena Patterson / Phil Kolodychuk | Canadian Sheep Federation | Veterinary Drugs | Fee Setting |
| 40 | Dan Demers | Candian Consumer Specialty Prodcuts Association (CCSPA) | Disinfectants | Fee Setting |
| 41 | Dan Demers | Candian Consumer Specialty Prodcuts Association (CCSPA) | Disinfectants | Fee Setting |
| 42 | Dianne Azzarello | Celgene Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 43 | Dianne Azzarello | Celgene Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Penalty Provision |
| 44 | Jeremy McLain | Celling | Medical Devices | Fee Setting |
| 45 | Anne Goodbody | Centre for Probe Development and Commercialization | Radiopharmaceutical Drug | Mitigation Measures |
| 46 | Don Sawchuk | CEVA Animal Health Inc. | Veterinary Drugs | Fee Setting |
| 47 | Steve Leech | Chicken Farmers of Canada | Veterinary Drugs | Fee Setting |
| 48 | Norm Morikawa | Communications & Power Industries Canada Inc. | Medical Devices | Annual Fee Adjustment |
| 49 | Brian Courtney | Conavi Medical Inc | Medical Devices | Fee Setting |
| 50 | Gerry Harrington | Consumer Health Products Canada | Non-prescription Drugs | Fee Setting |
| 51 | Richard Parcels | Cosmetics Alliance Canada | Non-prescription Drugs | Annual Fee Adjustment |
| 52 | Richard Parcels | Cosmetics Alliance Canada | Non-prescription Drugs | Fee Setting |
| 53 | Richard Parcels | Cosmetics Alliance Canada | Non-prescription Drugs | Performance Standards |
| 54 | Richard Parcels | Cosmetics Alliance Canada | Non-prescription Drugs | Penalty Provision |
| 55 | Cathy J Shupac | D&C Mobility Solutions Inc. | Non-prescription Drugs | Small Business |
| 56 | Ana Breivik on behalf of William Chick | DSA Consultants on behalf of Chifam Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Small Business |
| 57 | Ana Breivik on behalf of William Chick | DSA Consultants on behalf of Chifam Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Mitigation Measures |
| 58 | Ana Breivik on behalf of RMC Healthcare Inc. | DSA Consultants on behalf of RMC Healthcare Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Mitigation Measures |
| 59 | Ana Breivik on behalf of TERUMO BCT (Canada) Inc. | DSA Consultants on behalf of TERUMO BCT (Canada) Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Small Business |
| 60 | Ana Breivik on behalf of Mark Moody | DSA Healthcare Imports | Pharmaceuticals (Innovator/Biologic Drugs | Mitigation Measures |
| 61 | Kristy House | Equestrian Canada | Veterinary Drugs | Fee Setting |
| 62 | Kristy House | Equestrian Canada | Veterinary Drugs | Specific Fee Line Changes |
| 63 | Kristy House | Equestrian Canada | Veterinary Drugs | Annual Fee Adjustment |
| 64 | Kristy House | Equestrian Canada | Veterinary Drugs | Performance Standards |
| 65 | Vassilios Christodoulopoulos | Euro-Pharm International Canada Inc. | Generics | Penalty Provision |
| 66 | Vassilios Christodoulopoulos | Euro-Pharm International Canada Inc. | Generics | Small Business |
| 67 | Vassilios Christodoulopoulos | Euro-Pharm International Canada Inc. | Generics | Timing of Payment |
| 68 | Tarik Henein | Generic Medical Partners Inc. |
Generics | Fee Setting |
| 69 | John Cockhill | Grifols Canada Ltd | Pharmaceuticals (Innovator/Biologic Drugs | Mitigation Measures |
| 70 | John Cockhill | Grifols Canada Ltd | Pharmaceuticals (Innovator/Biologic Drugs | Annual Fee Adjustment |
| 71 | Lisa Chartrand | Hoffmann-La Roche Ltd | Pharmaceuticals (Innovator/Biologic Drugs | Penalty Provision |
| 72 | Lisa Chartrand | Hoffmann-La Roche Ltd | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 73 | Wm.H.L.(Bill) desBarres | Horse Welfare Alliance of Canada | Veterinary Drugs | Fee Setting |
| 74 | Gianna Zecchini | Inter Medico | Medical Devices | Fee Setting |
| 75 | Margaret Wheler | Janssen Canada Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 76 | Margaret Wheler | Janssen Canada Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Penalty Provision |
| 77 | Margaret Wheler | Janssen Canada Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Specific Fee Line Changes |
| 78 | Margaret Wheler | Janssen Canada Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Specific Fee Line Changes |
| 79 | Lesia Babiak | Johnson & Johnson Family of Companies in Canada | Medical Devices | Mitigation Measures |
| 80 | Lesia Babiak | Johnson & Johnson Family of Companies in Canada | Medical Devices | Specific Fee Line Changes |
| 81 | Lesia Babiak | Johnson & Johnson Family of Companies in Canada | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 82 | Lesia Babiak | Johnson & Johnson Family of Companies in Canada | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 83 | Lesia Babiak | Johnson & Johnson Family of Companies in Canada | Pharmaceuticals (Innovator/Biologic Drugs | Penalty Provision |
| 84 | Lesia Babiak | Johnson & Johnson Family of Companies in Canada | Non-prescription Drugs | Specific Fee Line Changes |
| 85 | Rick Jeysman | KVR Pharmaceuticals (early clinical stage) | Pharmaceuticals (Innovator/Biologic Drugs | Mitigation Measures |
| 86 | Robert Crabtree | Linde Canada Limited | Pharmaceuticals (Innovator/Biologic Drugs | Mitigation Measures |
| 87 | Robert Crabtree | Linde Canada Limited | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 88 | Nancy Abbey | MEDEC - Canada's Medical Technology Companies | Medical Devices | Fee Setting |
| 89 | Nancy Abbey | MEDEC - Canada's Medical Technology Companies | Medical Devices | Fee Setting |
| 90 | Nancy Abbey | MEDEC - Canada's Medical Technology Companies | Medical Devices | Fee Setting |
| 91 | Nancy Abbey | MEDEC - Canada's Medical Technology Companies | Medical Devices | Annual Fee Adjustment |
| 92 | Nancy Abbey | MEDEC - Canada's Medical Technology Companies | Medical Devices | Mitigation Measures |
| 93 | Nancy Abbey | MEDEC - Canada's Medical Technology Companies | Medical Devices | Performance Standards |
| 94 | Nancy Abbey | MEDEC - Canada's Medical Technology Companies | Medical Devices | Penalty Provision |
| 95 | Nancy Abbey | MEDEC - Canada's Medical Technology Companies | Medical Devices | Specific Fee Line Changes |
| 96 | Kevin Murray | Medline Canada Corp. | Medical Devices | Fee Setting |
| 97 | Aideen Kennedy | Medtronic of Canada | Medical Devices | Mitigation Measures |
| 98 | Casey Vander Ploeg | National Cattle Feeders' Association | Veterinary Drugs | Fee Setting |
| 99 | Casey Vander Ploeg | National Cattle Feeders' Association | Veterinary Drugs | Annual Fee Adjustment |
| 100 | Casey Vander Ploeg | National Cattle Feeders' Association | Veterinary Drugs | Performance Standards |
| 101 | Larry Colero | Novo Nordisk Canada Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Performance Standards |
| 102 | Jenn MacTavish | Ontario Sheep Farmers | Veterinary Drugs | Fee Setting |
| 103 | Jenn MacTavish | Ontario Sheep Farmers | Veterinary Drugs | Fee Setting |
| 104 | Pfizer Canada Inc. | Pfizer Canada Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Mitigation Measures |
| 105 | Pfizer Canada Inc. | Pfizer Canada Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Timing of Payment |
| 106 | Pfizer Canada Inc. | Pfizer Canada Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 107 | Pfizer Canada Inc. | Pfizer Canada Inc. | Pharmaceuticals (Innovator/Biologic Drugs | Specific Fee Line Changes |
| 108 | Pfizer Consumer Healthcare, a division of Pfizer Canada Inc. | Pfizer Canada Inc. | Non-prescription Drugs | Fee Setting |
| 109 | Pfizer Consumer Healthcare, a division of Pfizer Canada Inc. | Pfizer Canada Inc. | Non-prescription Drugs | Specific Fee Line Changes |
| 110 | Pfizer Consumer Healthcare, a division of Pfizer Canada Inc. | Pfizer Canada Inc. | Non-prescription Drugs | Specific Fee Line Changes |
| 111 | Dave Saucier | Responsible Distribution Canada | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 112 | Nicole Abou Abou Nakad | Roche Diagnostics Canada | Medical Devices | Mitigation Measures |
| 113 | Nicole Abou Abou Nakad | Roche Diagnostics Canada | Medical Devices | Mitigation Measures |
| 114 | Sani Marc | Sani Marc | Disinfectants | Performance Standards |
| 115 | Stephanie Fiorini-Senderovich | Sanis Health Inc. |
Generics | Small Business |
| 116 | Jonathan Hare | Telemark Veterinary Consulting | Veterinary Drugs | Fee Setting |
| 117 | Angelina Habimana | Teva Canada Innovation | Pharmaceuticals (Innovator/Biologic Drugs | Performance Standards |
| 118 | Shan Chaudhuri | The Clorox Company of Canada Ltd | Disinfectants | Fee Setting |
| 119 | Shan Chaudhuri | The Clorox Company of Canada Ltd | Disinfectants | Annual Fee Adjustment |
| 120 | Shan Chaudhuri | The Clorox Company of Canada Ltd | Disinfectants | Annual Fee Adjustment |
| 121 | Malenka Georgiou | Turkey Farmers of Canada | Veterinary Drugs | Fee Setting |
| 122 | Malenka Georgiou | Turkey Farmers of Canada | Veterinary Drugs | Performance Standards |
| 123 | Ron Boch | Vaccine Industry Committee | Pharmaceuticals (Innovator/Biologic Drugs | Fee Setting |
| 124 | Ron Boch | Vaccine Industry Committee | Pharmaceuticals (Innovator/Biologic Drugs | Performance Standards |
| 125 | Steve Vivier | Vivier Canada Inc. | Non-prescription Drugs | Fee Setting |
| 126 | Enoch Owusu | Zimmer Biomet | Medical Devices | Fee Setting |
| 127 | Enoch Owusu | Zimmer Biomet | Medical Devices | Mitigation Measures |
Report a problem or mistake on this page
- Date modified: